DECEMBER 2015 ARTICLE LIST >>
PharmaTutor (December- 2015)
Print-ISSN: 2394 - 6679
e-ISSN: 2347 - 7881
(Volume 3, Issue 12)
Received On: 12/07/2015; Accepted On: 12/08/2015; Published On: 01/12/2015
AUTHORS: Vivek P. Chavda*, Moinuddin M. Soniwala
Department of Pharmaceutics,
B.K. Mody Government Pharmacy College, (Affiliated to Gujarat Technological University)
Rajkot, Gujarat (India)
*vivek7chavda@gmail.com
ABSTRACT: The aim of this study was to investigate and evaluation of delayed release enteric coated paracetamol tablets. Successful delivery of drugs specifically to the intestine requires the protection of drug from being released in stomach. PCM core tablets were prepared with and without superdisintigrant using wet granulation method. Dip coating method is used for coating were different concentration of Eudragit L100 is used as coating agent. Preformulation studies like angle of repose, bulk density, tapped density, porosity, Carr's index, Hausner's ratio were performed. The FDT2 batch shows the highest drug release at end of total 135 min of 94.13 % which are the satisfactorily promising results. So, we can conclude that the FDT2 is the optimized batch among all three batches. From the reproducible results obtained from the executed experiments it can be concluded that Eudragit L 100 can be used as enteric coated polymer. These results reflect that PCM can be successfully enteric coated in order to prevent its release in the stomach and facilitate rapid release of the drug in the duodenum, due to the presence of superdisintegrant. Formulating these enteric coated tablets could increase patient compliance by decreasing adverse drug reactions (ADRS) associated with PCM therapy.
How to cite this article: VP Chavda, MM Soniwala; Formulation development and evaluation of delayed release enteric coated Paracetamol tablets; PharmaTutor; 2015; 3(12); 35-39
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1. George M., Grass I.V., Robinson J.R.; Sustained and Controlled release drug delivery systems; Marcel Dekker, New York, 1978, 124-127.
2. Rishabha M. P., Srivastava M., and Bansal M., Formulation and optimization of Formulation and optimization of using pectin as release modifier. Intl. J. Drug. Development and Res., 2010. 2(2); 330-335.
3. Rupesh K., Archana D., Kajale Keshao P., Giradkar V., Formulation and development of enteric coated dosage form using ketorolac tromethamine, International Journal of Pharmaceutical Research and Development, 2010; 2(8); 126-135.
4. Senthil K., Ashokkumar S., Ezhilmuthu R.P.; Formulation and evaluation of didanosine enteric coated sustained release tablet; J Biomed Sci and Res; 2010; 2(3), 126-131.
5. Anroop N., Rachna G., Rachna K., Shery J., Mahesh A.; Formulation and Evaluation of Enteric Coated Tablets of Proton Pump Inhibitor; Journal of Basic and Clinical Pharmacy; 2010; 1(4); 45-49.
6. Singh C., Kumar R., Agarwal K., Nema K.; Development and evaluation of enteric coated tablet containing diclofenac sodium; International Journal of Pharmaceutical Sciences and Nanotechnology; 2009; 2(1); 443-449.
7. Vivek U., Haranadh S., Sreerama T., Seetha D.; Formulation and invitro evaluation of enteric coated tablets of didanosine; Pharmanest - An International Journal of Advances In Pharmaceutical Sciences; 2011; 2 (1); 40-45.
8. Damodharan N., et al; F.D.A.E.O.D.R.D.T., International Journal of Pharmacy and Pharmaceutical Sciences; 2010; 2(1); 116-119.
9. Patel M.R., et al.; "Formulation and evaluation of doxycycline hydrochloride delayed release enteric coated tablets", Der Pharmacia Lettre; 2010, 4(1); 249-255.
10. Subramaniam K., et al.; "Formulation And Evaluation Of Aspirin Delayed Release Tablet." International Journal Of Comprehensive Pharmacy,2010,4(02); 1-3.
11. Rakesh T., Prasant P., Rabiprazole sodium delayed release multiparticulates: Effect of enteric coating layer on product performance. Journal of Advance Pharmaceutical Technology & Research, 2011; 2(3); 184-191.
.png)
